Octreotide oral - Chiasma

Drug Profile

Octreotide oral - Chiasma

Alternative Names: Chiasma Investigational Product 1; CHIP-1; Mycapssa; Octreolin; Octreotide acetate - Chiasma; Oral Octreotide; RG3806

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chiasma
  • Class Antineoplastics; Antisecretories; Cyclic peptides; Indoles; Somatostatins
  • Mechanism of Action Growth hormone releasing factor antagonists; Somatostatin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acromegaly
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Acromegaly
  • Discontinued Portal hypertension

Most Recent Events

  • 01 Sep 2017 Chiasma initiates the OPTIMAL phase III trial for Acromegaly in USA and Hungary (NCT03252353)
  • 23 Aug 2017 Chiasma plans the OPTIMAL phase III trial for Acromegaly in USA, Canada, Denmark, Germany, Hungary, Israel, Italy, Netherlands, Poland, Romania, Sweden, Turkey and United Kingdom (NCT03252353)
  • 01 Feb 2016 Chiasma initiates a phase III trial for Acromegaly in USA (NCT02685709)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top